RxDoctor Payments Data

Tayler Ebert, APRN

Family · Valdosta, GANPI 1710658042

Payments from drug & device makers

$10,479in general payments, 2019–2025

Across 451 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$801
  • Lundbeck LLC$792
  • Lilly USA, LLC$698
  • AbbVie$691
  • Livanova USA, Inc.$622
  • Jazz Pharmaceuticals Inc.$570
  • plus $6K from 42 others

What the payments were for

  • Travel & lodging$2352%
  • Food & beverage$10,16797%
  • Education$771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,479 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$31,175
Medicare patients
172
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate92$115,535
Nurtec OdtRimegepant Sulfate52$93,170
UbrelvyUbrogepant45$52,413
QuliptaAtogepant41$46,085
BriviactBrivaracetam26$38,444
AptiomEslicarbazepine Acetate14$33,504
Emgality SyringeGalcanezumab-Gnlm22$29,339
Emgality PenGalcanezumab-Gnlm38$26,809
NeuproRotigotine24$21,849
ValtocoDiazepam23$21,841
Aimovig AutoinjectorErenumab-Aooe18$17,673
NuedextaDextromethorphan Hbr/Quinidine11$11,481
Levetiracetam112$4,657
Carbamazepine ErCarbamazepine17$2,769
Lacosamide33$2,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$801$115,53592 claims
AbbVieUbrelvy, Qulipta$691$98,49886 claims
PfizerNurtec Odt$385$93,17052 claims
UCB, Inc.Briviact, Neupro$346$60,29350 claims
Sunovion Pharmaceuticals Inc.Aptiom$182$33,50414 claims
Neurelis, Inc.Valtoco$339$21,84123 claims
Avanir Pharmaceuticals, Inc.Nuedexta$62$11,48111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →